Benitec settles another lawsuit

By Melissa Trudinger
Tuesday, 24 August, 2004

RNAi company Benitec (ASX: BLT) has settled its second patent infringement lawsuit in two weeks, giving US company Genscript Corporation a non-exclusive worldwide licence to manufacture and sell DNA-directed RNAi (ddRNAi) products.

The lawsuit was one of three filed on March 22, 2004 against US companies Ambion, Genscript and Nucleonics. Ambion was granted a licence as part of a settlement announced on August 10. Financial details of the settlement and licence were not disclosed.

The company has also been granted a second UK patent related to its ddRNAi technology for use of ddRNAi expressed as hairpins in vertebrate animal cells, bringing the number of issued patents in the company's portfolio to eight.

Related News

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd